[Teriparatide (parathyroid hormone) for treaing osteoporosis in women in post-menopause]
Department of Science and Technology - Brazilian Health Technology Assessment General Coordination
Record ID 32006001470
Portuguese
Authors' objectives:
To evaluate the effectiveness and safety of the recombinant human parathyroid hormone (Teriparatide) in the treatment of osteoporosis in the postmenopause.
Authors' recommendations:
As administered in low doses (20mg) and intermittently Teriparatide seems to reduce vertebral (67%) and non-vertebral (38%) fractures, and increases the column and fermoral bone mineral density. Longer studies are necessary to provide conclusions about safety and persistence of therapeutical effects.
Details
Project Status:
Completed
Year Published:
2005
URL for published report:
http://portal2.saude.gov.br/rebrats/visao/estudo/detEstudo.cfm?codigo=130&evento=6&v=true
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Brazil
MeSH Terms
- Female
- Bone Density Conservation Agents
- Osteoporosis
- Teriparatide
Contact
Organisation Name:
Coordenação-Geral de Fomento à Pesquisa e Avaliação de Tecnologias em Saúde, Departamento de Ciência e Tecnologia
Contact Address:
Ministerio da Saude, Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia, Esplanada dos Ministerios, Edificio sede; bl "G" - 8 andar - SL 834, CEP: 70058-900, Brasilia, DF Brazil, Tel: +55 61 3315 3197 Fax: +55 61 3315 3850
Contact Name:
suzanne.jacob@saude.gov.br
Contact Email:
suzanne.jacob@saude.gov.br
Copyright:
Department of Science and Technology - Brazilian Health Technology Assessment General Coordination (DECIT-CGATS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.